Brokerage Picks: Tatva Chintan, Suzlon Energy Poised for 60-70% Upside

• Brokerage houses recommend 'buy' for Tatva Chintan Pharma Chem and Suzlon Energy, projecting 60-70% upside.
• ICICI Securities raised Tatva Chintan's target price to ₹1,955, citing strong Q3FY26 recovery in SDA and PASC segments.
• Tatva Chintan's SDA segment saw 132% YoY growth, with continued growth expected from new orders and Euro-7 norms.
• Motilal Oswal maintained a ₹74 target for Suzlon Energy, despite concerns over wind energy's declining share in tenders.
• Suzlon Energy's risk-reward is attractive at current prices, with potential for total wind capacity growth despite share decline.

Why It Matters: Tatva Chintan Pharma Chem and Suzlon Energy are recommended buys with significant upside potential.